Liver Center News

Yale School of Medicine's Department of Internal Medicine is pleased to announce the creation of the Endowed Catalyst Fund in Rheumatology, Allergy and Immunology. The fund will be used to support innovation in research and clinical care in the Department of Internal Medicine Section of Rheumatology, Allergy and Immunology.

Until very recently, no treatment options were available for metabolic-associated steatolic liver disease (MASLD) (previously called non-alcoholic fatty liver disease). The Food and Drug Administration recently approved resmetirom, the first therapy for the more severe form of MASLD, but there remains a need for a generic, affordable treatment option for patients. Bubu Banini, MD, PhD, was recently awarded a $3.05 million R01 grant by the National Institutes of Health (NIH) for a five-year research project to investigate the feasibility of oral digoxin as a treatment option for these patients.

Lisa Korn, MD, PhD, instructor of medicine (rheumatology, allergy and immunology) has been selected to receive the 2024 Iva Dostanic, MD, PhD, Physician-Scientist Trainee Award.

Wajahat Mehal, MD, professor of medicine (digestive diseases), discusses a new treatment for nonalcoholic steatohepatitis.

An openness to collaboration is just one factor in the popularity of team science at YSM.

As a part of our “Meet Yale Internal Medicine” series, today’s feature is on Romina Fiorotto, PhD, assistant professor (digestive diseases and pathology).

Yale researchers have collaborated with other experts in the field of hepatocellular carcinoma (HCC), or liver cancer, to develop the most recent American Association for the Study of Liver Diseases (AASLD) practice guidance for liver cancer.

Yale has made advances that have changed how doctors and patients grapple with diabetes.

The next era of obesity medicine